Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316060 | 0.89 | POLB (0.42) | CYP1A2TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15934091 | 0.86 | KDM4E (0.44) | CYP1A2TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL25980626 | 0.83 | MEN1 (0.38) | TDP1SMN1; SMN2ALDH1A1POLBHTT | |
| SCHEMBL25588991 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1POLBHTTLMNA | |
| SCHEMBL20436763 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1POLBHTTLMNA | |
| SCHEMBL19661315 | 0.82 | HTR1A (0.38) | CYP1A2TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15934092 | 0.80 | KDM4E (0.47) | CYP1A2TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15934122 | 0.80 | TDP1 (0.43) | CYP1A2TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL20464009 | 0.80 | MEN1 (0.35) | SMN1; SMN2ALDH1A1POLBHTTLMNA | |
| SCHEMBL14415917 | 0.79 | KMT2A (0.38) | TDP1SMN1; SMN2ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038956-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3554554-B1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS INC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-10947533-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10888578-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| WO-2020023688-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20140213737-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038956-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHY | UTRN, MTPN, SMN1; SMN2 | CYP1A2 4465/4885TDP1 101/4885SMN1; SMN2 3/4885 |
| US-11382981-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | CYP1A2 4832/4885TDP1 757/4885SMN1; SMN2 2/4885 |
| US-10888578-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | CYP1A2 4836/4885TDP1 755/4885SMN1; SMN2 2/4885 |
| US-20140213737-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | RNGTT, SPOUT1, MRPL21 | CYP1A2 4831/4885TDP1 754/4885SMN1; SMN2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.